lenvatinib

Also Known As:

4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide; 4-(3-chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-chloro-4-(N'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide; E 7080; E-7080; E-7080 mesylate; E7080; E7080 mesylate; ER-203492-00; Lenvima; N-(4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)-N'-cyclopropylurea monomethanesulfonate; lenvatinib mesilate; lenvatinib mesylate; lenvatinib metabolite M2; lenvatinib methanesulfonate

Networked: 1553 relevant articles (299 outcomes, 400 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kudo, Masatoshi: 38 articles (09/2022 - 01/2017)
2.	Hiraoka, Atsushi: 31 articles (06/2022 - 01/2019)
3.	Tada, Toshifumi: 28 articles (06/2022 - 01/2019)
4.	Kumada, Takashi: 27 articles (06/2022 - 01/2019)
5.	Atsukawa, Masanori: 26 articles (06/2022 - 01/2019)
6.	Itobayashi, Ei: 26 articles (06/2022 - 01/2019)
7.	Toyoda, Hidenori: 26 articles (06/2022 - 01/2019)
8.	Dutcus, Corina E: 26 articles (01/2021 - 02/2015)
9.	Ishikawa, Toru: 25 articles (06/2022 - 01/2019)
10.	Hiasa, Yoichi: 24 articles (06/2022 - 01/2019)

Related Diseases

1.	Hepatocellular Carcinoma (Hepatoma) 09/01/2020 - "Preserved liver function may be an important factor affecting therapeutic efficacy in hepatocellular carcinoma patients treated with lenvatinib, but not all patients can be treated while preserving liver function. " 01/01/2023 - "Purpose: Results from the LAUNCH trial suggest transarterial chemoembolization (TACE) in combination with lenvatinib is significantly more effective than lenvatinib as a first-line treatment option for advanced hepatocellular carcinoma (HCC). " 01/01/2021 - "Lenvatinib is the latest and promising agent that has demonstrated a significant improvement of progression-free survival in advanced hepatocellular carcinoma (HCC). " 07/01/2021 - "Overall, our study found that in this demographically and clinically diverse sample, results affirm findings from prior studies that found lenvatinib is an effective treatment for patients with unresectable hepatocellular carcinoma." 04/01/2015 - "In addition, an ongoing global, phase 3 trial is evaluating the use of lenvatinib as first-line treatment in unresectable hepatocellular carcinoma. "
2.	Neoplasms (Cancer) 05/01/2022 - "Multikinase inhibitors that inhibit angiogenesis, such as lenvatinib, have proven effective in several other malignancies, and may be a viable option for mPPGL. " 12/01/2023 - "Lenvatinib is safe and effective for advanced HCC in patients with Child-Pugh A, even with high tumor burden. " 11/24/2020 - "Alternatively, Lenvatinib, regardless of mutational status, reported good results and was approved in Japan for treating unresectable tumors. " 01/01/2019 - "Combination of lenvatinib with anti-Gr-1 antibody ameliorated lenvatinib's expansion of MDSCs and significantly improved lenvatinib's anti-tumor effect. " 11/01/2017 - "Tumor growth was significantly inhibited and tumor‑bearing mice demonstrated an improved survival rate following treatment with lenvatinib. "
3.	Thyroid Neoplasms (Thyroid Cancer) 01/01/2020 - "Lenvatinib has proven efficacy in progressive, radioiodine- (RAI-) refractory thyroid cancer (TC). " 01/01/2023 - "In the phase 3 SELECT study, lenvatinib significantly improved prognostic outcomes vs. placebo in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). " 01/01/2022 - "Background: Lenvatinib treatment has shown a significant improvement in progression-free survival in patients with metastatic, progressive, radioiodine-refractory differentiated thyroid cancer, although its use is associated with considerable toxicity. " 01/01/2021 - "Lenvatinib is effective in the treatment of RR thyroid carcinoma. " 01/01/2021 - "Subgroup analysis shows that lenvatinib is effective for all patients with RR thyroid carcinoma, regardless of age, histological subtypes, radiological subtypes and mutation status. "
4.	Renal Cell Carcinoma (Grawitz Tumor) 11/01/2015 - "Further study of lenvatinib is warranted in patients with metastatic renal cell carcinoma. " 01/01/2023 - "Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma." 01/01/2022 - "In this report, we examined two doses of lenvatinib (the approved 18-mg dose and a lower dose of 14 mg) in people with advanced renal cell carcinoma to determine whether the lower dose (which was increased to the approved 18-mg dose after the first treatment cycle) could improve safety without affecting efficacy. " 01/01/2018 - "Lenvatinib for the treatment of renal cell carcinoma." 08/01/2015 - "Lenvatinib Extends Survival in Metastatic Renal-Cell Carcinoma."
5.	Neoplasm Metastasis (Metastasis) 08/01/2021 - "Lenvatinib was effective for treating the metastases in the lungs and spleen. " 04/20/2020 - "At this point, the patient was doing well, suggesting that lenvatinib was effective in treating the MTC liver metastasis and may be one of the treatment for advanced MTC caused by C634Y mutation in the RET gene." 01/01/2023 - "Unfortunately, recurrence and metastasis occurred soon after radical surgery and standard first-line treatment with lenvatinib. " 06/01/2022 - "In this study, we investigate lung cavitation during treatment with lenvatinib in ATC patients with lung metastasis. " 01/01/2022 - "In this study, we demonstrated that lenvatinib induced extrinsic/intrinsic apoptosis and suppressed the metastasis of HCC both in vitro and in vivo. "

Related Drugs and Biologics

1.	Sorafenib (BAY 43-9006)
2.	pembrolizumab
3.	Immune Checkpoint Inhibitors
4.	Tyrosine Kinase Inhibitors
5.	lenvatinib
6.	Bevacizumab (Avastin)
7.	Phosphotransferases (Kinase)
8.	atezolizumab
9.	Iodine
10.	Everolimus

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Radiotherapy
4.	Immunotherapy
5.	Aftercare (After-Treatment)